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OBJECTIVES: Obtaining access to HIV/AIDs medications can be a challenge for
low-income people with HIV who currently cannot obtain Medicaid benefits be-
cause they are considered too healthy for assistance but too poor to purchase
coverage on their own. We would like to evaluate the current level of access to
medication for uninsured individuals living with HIV/AIDs and assess how access
to these drugs might change over time. METHODS: We limited the scope of our
review to the top ten US states with the largest HIV/AIDs populations: New York,
California, Florida, Texas, Georgia, New Jersey, Pennsylvania, Illinois, Maryland,
and Massachusetts. We then reviewed the current structure of their AIDs Drug
Assistance Programs (ADAPs) and evaluated the robustness of the benefit and its
respective formulary. Our next step was to then project how this populationmight
benefit from the expansion of Medicaid. RESULTS: New York and California have
some of the most comprehensive benefits covering 465 and176 HIV/AIDS-related
medications, respectively. Texas, on the other hand, appears to be themost restric-
tive, covering only 44 medications. Looking forward, some states could see larger
increases in the number of uninsured HIV/AIDS patients that now fall under their
Medicaid programs. Texas, Virginia, and North Carolina could potentially see up-
wards of a 35% increase in Medicaid enrollees with HIV/AIDs. CONCLUSIONS: Half
of the states reviewed have waiting lists for their ADAPs and two of the states have
already extended Medicaid benefits to AIDs/HIV patients via a 1115 waiver. To that
end, it seems reasonable to conclude that while the expansion of Medicaid will
generally be beneficial for the uninsured living with HIV/AIDs, it’s impact will be
felt more so in some states while not as much in others.
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OBJECTIVES: The study aimed to assess availability and stock outs of antimalarial
drugs in public and private secondary health care facilities in two cities of Pakistan;
Islamabad (Federal capital) and Rawalpindi (twin city).METHODS: A comparative,
cross-sectional study was designed to evaluate anti-malarial drugs stock outs in
public and private secondary health care facilities in the two cities. The anti-ma-
larial drugs records were collected from the pharmacies located in the health care
facilities. Pre-validated tools i.e., WHO facility indicator form and USAID inventory
indicator and drug stock outs form were used to collect data regarding availability
and stock outs of anti-malarial drugs. After the data collection, data were coded
and analyzed by using SPSS version 16. RESULTS: The total average number of
day’s stock out of anti-malarial drugs at public secondary healthcare facilities was
230.3 and 291.9 days in Islamabad and Rawalpindi respectively. While on the other
hand total average number of day’s stock out of anti-malarial drugs at private
secondary health care facilities was 170.2 and 210.4 days in Islamabad and Rawal-
pindi cities, respectively. A pharmacist wasmostly available in all the public health
care facilities but in few of the private health care facilities. Moreover a significant
difference (p  0.05) was noted in anti malarial drug stock outs among different
public and private healthcare facilities in the two cities. CONCLUSIONS: The find-
ings suggest major stock outs of anti-malarial drugs in both public and private
health care facilities; however the situation was more prevalent in the public sec-
tor. Essential drug list was not available and being followed. The role of pharmacist
comes under question in effective drug management in public health care facili-
ties.
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OBJECTIVES:This study compared pneumonia-related rehospitalizations and total
medical costs among patients hospitalized for pneumonia and treated with lin-
ezolid or vancomycin post-discharge.METHODS: Two administrative claims data-
bases were pooled and adults hospitalized for pneumonia and treated with lin-
ezolid or vancomycin post-discharge from January 1, 2007 through September 30,
2009 were identified. Two pneumonia populations were studied: 1) “broad group”
that included all pneumonia ICD-9 codes; and 2) “narrow group” that included
ICD-9 codes consistentwith the FDA labeled pneumonia indication.Within 42 days
following hospital discharge, pneumonia-related rehospitalizations and totalmed-
ical costs were compared between linezolid and vancomycin users. Multivariable
regression analyseswere performed, controlling for index hospitalization length of
stay, clinical and demographic factors. RESULTS: The “broad group” consisted of
1,468 patients (46% linezolid), while 417 patients (61% linezolid) met the “narrow”
ICD-9 code criteria. Unadjusted pneumonia-related rehospitalization rates were
lower for linezolid relative to vancomycin in both the “broad” (9% vs. 15%, p 0.01)
and “narrow” (6% vs. 15%, p  0.01) groups. In the multivariate analysis, linezolid
users were less likely to have a pneumonia-related rehospitalization in both the
“broad” (OR0.59, 95%CI: 0.42 – 0.83) and “narrow” (OR0.34, 95%CI: 0.17 – 0.69)
populations. Adjusted total costs were significantly lower for linezolid users in the
“broad” population (cost savings: $1525; 95%CI: $1423 - $1627). No significant dif-
ference in cost savings was observed in the “narrow” population (adjusted point
estimate of cost savings with linezolid: $341; p  0.63). CONCLUSIONS: Among
commercially insured patients treated with either linezolid or vancomycin follow-
ing hospitalization for pneumonia, linezolid was associated with significantly
lower pneumonia-related re-hospitalizations and total direct medical costs in the
“broad” population of all pneumonia patients. In the narrower, FDA labeled-indi-
cation group, significantly lower pneumonia-related re-hospitalizations occurred
among linezolid users but the between-treatment difference in total adjustedmed-
ical costs was not significant.
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OBJECTIVES: Aims of this study were to quantify the expenditure for antiretroviral
(ARV) treatment in Italy, and to estimate the potential impact of the introduction of
generic antiretrovirals in the Italian pharmaceutical market. METHODS: Using a
data-set of pharmaceutical expenditure in Italy, we analysed the total expenses for
ARVs at national level. Since in the near future generic zidovudine (AZT), lamivu-
dine (3TC), nevirapine (NVP) and efavirenz (EFV) will be available in Italy, we cal-
culated the potential cost-saving, modeling scenarios with price reduction be-
tween 20%-60% of the originators prices. In sensitivity analyses, we assumed that
branded emtricitabine could be substituted by generic 3TC, and that fixed dose
combinations (FDC) could be partially substituted by single components with ge-
neric medicines. RESULTS: In 2010, €500.689.927 were spent for antiretroviral ther-
apies (total ARV use: 1.91 DDIs/1000 inhabitants/day), with an increase of 12.6%
compared with the 2009 expenditure. The most relevant proportion was attribut-
able to FDC, accounting for €238.826.599 (47.7% of total costs). The total percentage
of costs for ARVs related to the use of AZT, 3TC, NVP and EFV was 7.33%
(€36.713.056). Assuming the prescriptions of these drugs to be constant in next
years, different scenarios of price reduction (from 20% to 60%) for generic drugs
showed an estimated cost-saving ranging from €7.342.611 (1.47% of total ARV costs)
to €22.027.833 (4.40%). When including emtricitabine substitution by 3TC, cost-
saving rises to €7.435.738-22.307.213 (1.49-4.46%) and to €26.832.726-80.498.178
(5.36-16.08%) considering the unbundling of branded FDC. CONCLUSIONS: The
forthcoming availability of some antiretroviral generics could be an option for
safely and effectively cost-saving. However, in our study, the greater reduction of
costs has been estimated by FDC substitution, raising the potential dilemma of
increasing regimen complexity. Further studies will be needed to evaluate safety
and efficacy of FDC substitutionwith generics incorporating both treatment adher-
ence and pharmacoeconomic outcomes.
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OBJECTIVES: Despite recent advances in critical care, severe sepsis is one of the
world’s leading causes of death and remains both an important clinical challenge
and an economic burden to western health care systems. Our aim is to analyze the
costs and discharge status of severe sepsis in Spain and to examine the impact of
age in terms of hospital outcomes METHODS: Analysis of the 2008 nationwide
hospital discharge database. We identified cases based on the ICD-9-CM codes for
sepsis and organ dysfunction. We examined demographics, comorbidities, clinical
outcomes and hospital costs and performed a logistic regression analysis to iden-
tify factors associated with in-hospital mortality. We calculated hospital charges
based on the National Health Service charges for DRGs. To depict the amount of
resources spent to procure a given level of desired outcome (hospital survival) we
also determined the cost per survivor. RESULTS: A total of 37,746 cases were ana-
lyzed. Median age was 73 year (p25:59; p75:82); 58% were men, 28% surgical cases,
31% of cases had no associated comorbidity. In-hospital mortality was 45%. An
inverse relationship between survival rate and age was consistently observed after
adjusting by other clinical variables. Total costs of hospitalizations exceeded €500
million with 35% spent in patients aged 74 years. Age-related costs per survivor
were €19,538 in cases aged 1 year; €12,390 in those aged 1-14 years; €16,703 in
patients aged 15-44 years; €15,917 in patients 45-64 years, €13,828 in patients 65-74
years and €9,366 in those aged74 years. CONCLUSIONS: Severe sepsis associates
with highmortality and hospital-resources utilization. Age has a significant impact
on outcomes both from clinical and economic perspectives. Age is an independent
predictor of mortality. Costs per survivor, however, are substantially lower in el-
derly patients. These data will help inform health care decision-making and re-
source planning in the face of an ageing population.
PIN59
ASSESSING THE AWARENESS ABOUT HUMAN PAPILLOMAVIRUS (HPV) AND
ATTITUDE TOWARDS THE HPV VACCINE IN A COHORT OF MALE COLLEGE
STUDENTS
Medhekar RA, Hatfield MD, Sansgiry SS
University of Houston, Houston, TX, USA
OBJECTIVES: The Human Papillomavirus (HPV) infection is the most common sex-
ually transmitted disease in the United States. HPV infected males also put their
female partners at increased risk of cervical cancer. Recently a HPV vaccine was
approved for use in males aged 9-26 years. The purpose of this study was to assess
awareness regarding HPV and the vaccine amongst a cohort of male university
students. Further, we evaluated their attitude towards the HPV vaccine and its
relationship with awareness. METHODS: A self-administered anonymous survey
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